“Unreal world” or “real world” data in oral anticoagulant treatment of atrial fibrillation

Thrombosis and Haemostasis

Volumn 116, Issue 4, 2016, Pages 587-589

  Freedman, Ben ^a,b   Lip, Gregory Y H ^c,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ANZAC Research Institute   (Australia)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; VERAPAMIL; WARFARIN; FIBRINOLYTIC AGENT; VITAMIN K GROUP;

ATRIAL FIBRILLATION; BLEEDING; BLOOD CLOTTING DISORDER; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; EMBOLISM; HEART INFARCTION; HUMAN; META ANALYSIS (TOPIC); MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; DABIGATRAN; FIBRINOLYTIC AGENTS; HUMANS; VITAMIN K;

EID: 84989170913     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-08-0658     Document Type: Editorial

References (20)

1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151.
2. Potpara TS. Dabigatran in ’real-world’ clinical practice for stroke prevention in patients with non-valvular atrial fibrillation. Thromb Haemost 2015; 114: 1093–1098.
3. Seeger JD, Bykov K, Bartels DB, et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost 2015; 114: 1277–1289.
4. Villines TC, Schnee J, Fraeman K, et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost 2015; 114: 1290–1298.
5. Hylek EM, Ko D, Cove CL. Gaps in translation from trials to practice: Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation. Thromb Haemost 2014; 111: 783–788.
6. Lip GY, Clemens A, Noack H, et al. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost 2014; 111: 933–942.
7. Carmo J, Moscoso Costa F, Ferreira J, et al. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. Thromb Haemost 2016; 116: 754-763.
8. Romanelli RJ, Nolting L, Dolginsky M, et al. Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis. Circ Cardiovasc Qual Outcomes 2016; 9: 126–134.
9. Bjorck F, Sanden P, Renlund H, et al. Warfarin treatment quality is consistently high in both anti-coagulation clinics and primary care setting in Sweden. Thrombosis Res 2015; 136: 216–220.
10. Chan PH, Huang D, Hai JJ, et al. Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation. Heart Rhythm 2016; 13: 366–373.
11. Ho CW, Ho MH, Chan PH, et al. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of antico-agulation control. Stroke 2015; 46: 23–30.
12. Levine GN, Jeong YH, Goto S, et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nature Rev Cardiol 2014; 11: 597–606.
13. Hori M, Connolly SJ, Zhu J, et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 2013; 44: 1891–1896.
14. Wang KL, Lip GY, Lin SJ, et al. Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis. Stroke 2015; 46: 2555–2561.
15. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172: 397–402.
16. Larsen TB, Gorst-Rasmussen A, Rasmussen LH, et al. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med 2014; 127: 650–656.e5.
17. Chan YH, Yen KC, See LC, et al. Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation. Stroke 2016; 47: 441–449.
18. Larsen TB, Skjoth F, Nielsen PB, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Br Med J (Clinical research ed). 2016; 353: i3189.
19. Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, et al. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. J Am Heart Assoc 2016; Epub ahead of print.
20. Lip GY, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among nonvalvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost 2016; Epub ahead of print.